Carl L. Gordon Acquires 47,502 Shares of MBX Biosciences, Inc. (NYSE:MBX) Stock

MBX Biosciences, Inc. (NYSE:MBX) Director Carl L. Gordon acquired 47,502 shares of the company’s stock in a transaction dated Friday, February 14th. The stock was acquired at an average price of $9.87 per share, for a total transaction of $468,844.74. Following the completion of the purchase, the director now directly owns 3,205,930 shares of the company’s stock, valued at $31,642,529.10. This trade represents a 1.50 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

MBX Biosciences Stock Performance

Shares of MBX opened at $10.88 on Friday. MBX Biosciences, Inc. has a 12-month low of $8.63 and a 12-month high of $27.50. The firm’s 50-day moving average price is $14.05.

Hedge Funds Weigh In On MBX Biosciences

Several institutional investors and hedge funds have recently added to or reduced their stakes in MBX. BNP Paribas Financial Markets bought a new position in MBX Biosciences during the fourth quarter valued at about $27,000. Virtus ETF Advisers LLC bought a new position in MBX Biosciences during the fourth quarter valued at about $64,000. Deutsche Bank AG bought a new position in MBX Biosciences during the fourth quarter valued at about $80,000. Corebridge Financial Inc. bought a new position in MBX Biosciences during the fourth quarter valued at about $103,000. Finally, Wells Fargo & Company MN bought a new position in MBX Biosciences during the fourth quarter valued at about $108,000.

MBX Biosciences Company Profile

MBX Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism.